Workflow
Nestlé appoints Jeff Hamilton as CEO Zone Americas, Steve Presley to retire from the company
GlobeNewswire· 2025-04-26 00:30
文章核心观点 - 雀巢任命Jeff Hamilton为美洲区首席执行官,原美洲区首席执行官Steve Presley退休 [2][3] 人事变动情况 - 雀巢董事会任命现任普瑞纳宠物护理欧洲区业务负责人Jeff Hamilton为美洲区首席执行官及集团执行董事会成员,7月1日起生效 [2] - 任职近30年的美洲区执行副总裁兼首席执行官Steve Presley将于4月30日退休,离开执行董事会及美洲区首席执行官岗位 [3] 相关评价与人物经历 - 雀巢首席执行官Laurent Freixe感谢Steve的长期服务,并期待Jeff推动美洲区增长战略 [4] - Jeff Hamilton 1991年在美国普瑞纳开始职业生涯,曾担任多个领导职位,拥有跨三个区域的国际工作经验,自2021年起担任普瑞纳宠物护理欧洲区首席执行官,拥有西北大学凯洛格管理学院工商管理硕士学位 [4] 联系方式 - 媒体联系:Christoph Meier,电话+41 21 924 2200,邮箱mediarelations@nestle.com [5] - 投资者联系:David Hancock,电话+41 21 924 3509,邮箱ir@nestle.com [5]
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
GlobeNewswire· 2025-04-26 00:06
文章核心观点 - 英国药品和保健品监管局(MHRA)授予Autolus Therapeutics公司的AUCATZYL(obecabtagene autoleucel)有条件上市许可,用于治疗复发或难治性B细胞前体急性淋巴细胞白血病(r/r B - ALL)成年患者,该许可基于FELIX研究结果,公司正与NICE和NHS合作以让英格兰符合条件患者使用此药 [1][4][6] 公司信息 - Autolus Therapeutics是一家处于早期商业阶段的生物制药公司,开发、制造和交付下一代T细胞疗法及候选产品,用于治疗癌症和自身免疫性疾病,拥有FDA批准和MHRA许可产品AUCATZYL及多个在研候选产品 [10] 药物信息 - AUCATZYL是一种B淋巴细胞抗原CD19嵌合抗原受体(CAR)T细胞疗法,设计有快速靶标结合解离率,以减少程序性T细胞过度激活,2024年11月8日获FDA批准,2025年4月25日获MHRA有条件上市许可,2024年4月向欧盟EMA提交监管申请 [12] 临床试验信息 - FELIX研究是一项针对r/r B - ALL成年患者的开放标签、多中心、单臂研究,结果于2024年11月发表在《新英格兰医学杂志》,153名患者中127名(83.0%)接受至少一次obecabtagene autoleucel输注并可评估,关键队列IIA(n = 94)中完全缓解/血液学未完全恢复的完全缓解(CR/CRi)率为76.6%,所有输注患者中位缓解持续时间为21.2个月,中位无事件生存期(EFS)为11.9个月,6个月和12个月无事件生存率分别为65.4%和49.5% [4] - 最常见的3级或更高级非实验室不良反应为未明确病原体的感染(32%)、发热性中性粒细胞减少症(24%)和细菌性感染性疾病(11%),127名患者中87名(68.5%)发生细胞因子释放综合征,3名(2.4%)为3级或更高级,29名(22.8%)发生免疫效应细胞相关神经毒性综合征,9名(7%)为3级或更高级 [4] 行业背景信息 - 急性淋巴细胞白血病(ALL)是一种侵袭性血癌,可累及淋巴结、脾脏、肝脏、中枢神经系统等器官,英国每年约有765例新诊断ALL病例,成人B - ALL一线治疗中多达50%患者最终会复发,r/r ALL成年患者生存率很低,传统治疗中位总生存期为8个月,标准治疗会引发严重毒性 [8] 有条件上市许可信息 - 有条件上市许可(CMAs)适用于满足重大未满足医疗需求的药物,如治疗严重和危及生命疾病且无满意治疗方法或药物具有重大治疗优势的情况,在综合临床数据未完成但预计很快可获得时授予,有效期一年,每年可续期并接受持续监管数据审查 [14] 后续进展信息 - Autolus于2024年第四季度提交obecabtagene autoleucel供英国国家健康与护理卓越研究所(NICE)评估,正与NICE和NHS合作,有望让英格兰符合条件患者使用该药物 [6]
Approval of Convertible Loan Note Amendments
GlobeNewswire· 2025-04-26 00:03
Global InterConnection Group announces the Approval of Convertible Loan Note Amendments following Agreement of the Atlantic SuperConnection Spin-Out and Supporting Right of First Refusal Process. Please see the full press release attached. Attachment Right of First Refusal for CLN investment ...
Availability of the 2024 Annual Report
GlobeNewswire· 2025-04-26 00:00
Foussemagne (France), April 25, 2025 – 6:00 pm CEST – McPhy Energy, manufacturer of alkaline electrolyzers, today announces that it has made available to the public and filed with the Autorité des marchés financiers its 2024 annual report (only available in French) for the year ended December 31, 2024. This report can be viewed on the Company's website (www.mcphy-finance.com), in the "Investors" > "Financial Publications" > "Financial Reports" section, in accordance with legal requirements. ABOUT MCPHY Spec ...
Maisons du Monde : Filing of the 2024 Universal Registration Document
GlobeNewswire· 2025-04-26 00:00
Maisons du Monde announces the release of its 2024 Universal Registration Document. The Document was filed with the Autorité des Marchés Financiers (AMF) this 25 April 2025, under the reference number D.25-0297. This 2024 Universal Registration Document (fiscal year ended on December 31, 2024) includes among other items: - the 2024 annual financial report, - the report prepared by the Board of Directors on corporate governance, - the sustainability report - the reports of the Statutory Auditors and informat ...
Distracted Driving Awareness Month: Mercury Insurance Offers Driving Tips That Could Save Lives
Prnewswire· 2025-04-26 00:00
Safe Driving May Also Offer Savings on Auto Insurance LOS ANGELES, April 25, 2025 /PRNewswire/ -- Each year, 1.19 million people are killed on roadways around the world, according to the U.S. Centers for Disease Control and Prevention. Traffic collisions are the leading cause of death for individuals ages five to 29. In a world inundated with technology and devices, distracted driving in particular is claiming thousands of lives. Many auto accidents could be avoided simply by following the rules of the road ...
Credit Agricole Nord de France - Resultats Financiers au 31 Mars 2025
GlobeNewswire· 2025-04-25 23:31
Lille, le 25 avril 2025 Résultats financiers au 31 Mars 2025 du Crédit Agricole Mutuel Nord de France Mars 2025 Mars 2024 Variation Activité : Encours de collecte globale 38 929 M€ 37 777 M€ 3,05% Encours de crédit* 28 728 M€ 28 703 M€ 0,09% Résultats sociaux* : Produit Net Bancaire 136,7 M€ 141,4 M€ -3,36% Résultat Brut d’Exploitation 32,5 M€ 42,9 M€ -24,15% <td styl ...
Advantage Solutions Announces Date for its First Quarter 2025 Financial Results and Conference Call
Newsfilter· 2025-04-25 23:30
ST. LOUIS, April 25, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ:ADV) announced today that it will release financial results for the first quarter at 7 a.m. EDT on May 12, 2025, followed by a conference call at 8:30 a.m. EDT on the same day. The conference call can be accessed live over the phone by dialing 1-800-267-6316, or for international callers, 1-203-518-9783. The conference ID is ADVQ1. Approximately three hours after the call, a replay will be available by dialing 1-844-512-2921, or ...
Lottery.com Files Amended Registration Statement on Form S-1
Newsfilter· 2025-04-25 23:30
FORT WORTH, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Lottery.com Inc. (NASDAQ:LTRY), a leading technology company a leading technology company in digital lottery, charitable sweepstakes and sports entertainment, today announced the filing of an amended registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC"). The filing is related to the registration of shares issuable under a $100 million committed stock purchase agreement ("SPA") with Generating Alpha Ltd., along with a ...
Pieno Žvaigždės AB, Financial statements for the year 2024
GlobeNewswire· 2025-04-25 23:30
Financial statements, Management report, Confirmation of the management, Audit opinion and Sustainability report for 2024 approved by the Annual General Shareholders' Meeting of Pieno Žvaigždės AB on 25 April 2025. Laimonas Vaškevičius CFO +370 5 246 1419 Attachments 2024_ar_en_eur_solo_ias_esef Pieno žvaigždės AB - CSRD limited assurance report EN Pieno_Zvaigzdes_AB-Opinion_24_IFRS_SA_ESEF_EN_esigned_20250328 ...